MX2015005059A - Fase cristalina de (3s,3s') 4,4'-disulfanodiilbis(acido 3-aminobutano-1-sulfonico) con l-lisina. - Google Patents

Fase cristalina de (3s,3s') 4,4'-disulfanodiilbis(acido 3-aminobutano-1-sulfonico) con l-lisina.

Info

Publication number
MX2015005059A
MX2015005059A MX2015005059A MX2015005059A MX2015005059A MX 2015005059 A MX2015005059 A MX 2015005059A MX 2015005059 A MX2015005059 A MX 2015005059A MX 2015005059 A MX2015005059 A MX 2015005059A MX 2015005059 A MX2015005059 A MX 2015005059A
Authority
MX
Mexico
Prior art keywords
crystalline phase
disulfanediylbis
aminobutane
lysine
sulfonic acid
Prior art date
Application number
MX2015005059A
Other languages
English (en)
Other versions
MX353693B (es
Inventor
Fabrice Balavoine
Jean-Marie Schneider
Gérard Coquerel
Nicolas Couvrat
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of MX2015005059A publication Critical patent/MX2015005059A/es
Publication of MX353693B publication Critical patent/MX353693B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26—Separation; Purification; Stabilisation; Use of additives
    • C07C319/28—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una nueva fase cristalina de (3S, 3S´) 4,4'-disulfanodiilbis (ácido 3-aminobutano-1-sulfónico) (ABSD) con L-lisina y a su uso, particularmente en la industria farmacéutica, y a procesos para la preparación de la misma. La invención también se refiere a composiciones farmacéuticas que contienen al menos una fase cristalina de (3S, 3S´) 4,4'-disulfanodiilbis (ácido 3-aminobutano-1-sulfónico) (ABSD) con L-lisina y al uso terapéutico o profiláctico de tal fase cristalina y a composiciones que comprenden la misma.
MX2015005059A 2012-10-22 2013-10-22 Fase cristalina de (3s,3s') 4,4'-disulfanodiilbis (ácido 3-aminobutano-1-sulfónico) con l-lisina. MX353693B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306307.5A EP2722327A1 (en) 2012-10-22 2012-10-22 Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
PCT/EP2013/072028 WO2014064077A1 (en) 2012-10-22 2013-10-22 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine

Publications (2)

Publication Number Publication Date
MX2015005059A true MX2015005059A (es) 2015-11-23
MX353693B MX353693B (es) 2018-01-24

Family

ID=47278723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005059A MX353693B (es) 2012-10-22 2013-10-22 Fase cristalina de (3s,3s') 4,4'-disulfanodiilbis (ácido 3-aminobutano-1-sulfónico) con l-lisina.

Country Status (30)

Country Link
US (2) US9278921B2 (es)
EP (2) EP2722327A1 (es)
JP (1) JP6317358B2 (es)
KR (1) KR102103407B1 (es)
CN (1) CN104768927B (es)
AR (1) AR093070A1 (es)
AU (1) AU2013336738B2 (es)
BR (1) BR112015008931B1 (es)
CA (1) CA2884914C (es)
CY (1) CY1119913T1 (es)
DK (1) DK2909169T3 (es)
EA (1) EA024460B1 (es)
ES (1) ES2658413T3 (es)
HK (1) HK1212321A1 (es)
HR (1) HRP20180189T1 (es)
HU (1) HUE036037T2 (es)
IL (1) IL237733B (es)
IN (1) IN2015DN02807A (es)
LT (1) LT2909169T (es)
ME (1) ME02955B (es)
MX (1) MX353693B (es)
NO (1) NO2909169T3 (es)
NZ (1) NZ706070A (es)
PL (1) PL2909169T3 (es)
PT (1) PT2909169T (es)
RS (1) RS56896B1 (es)
SI (1) SI2909169T1 (es)
TW (1) TWI643842B (es)
WO (1) WO2014064077A1 (es)
ZA (1) ZA201503574B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951562B (zh) * 2014-05-09 2016-04-20 四川九章生物化工科技发展有限公司 一种绿原酸晶型及其制备方法
WO2022225712A1 (en) * 2021-04-22 2022-10-27 Teva Pharmaceuticals International Gmbh Solid state forms of firibastat and processes for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1525188T3 (da) * 2002-07-16 2008-11-17 Inst Nat Sante Rech Med Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
EP2439192A1 (en) 2010-10-07 2012-04-11 Quantum Genomics Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)
WO2012138907A2 (en) * 2011-04-05 2012-10-11 Translational Genomics Research Institute Solid forms of curcumin

Also Published As

Publication number Publication date
EA201500438A1 (ru) 2015-09-30
PT2909169T (pt) 2018-02-26
AR093070A1 (es) 2015-05-13
CN104768927B (zh) 2017-06-09
HUE036037T2 (hu) 2018-06-28
SI2909169T1 (en) 2018-04-30
CA2884914C (en) 2021-01-05
LT2909169T (lt) 2018-04-25
NZ706070A (en) 2018-11-30
US20150284325A1 (en) 2015-10-08
ME02955B (me) 2018-07-20
TWI643842B (zh) 2018-12-11
MX353693B (es) 2018-01-24
NO2909169T3 (es) 2018-06-02
WO2014064077A1 (en) 2014-05-01
US20160221940A1 (en) 2016-08-04
CN104768927A (zh) 2015-07-08
EA024460B1 (ru) 2016-09-30
KR102103407B1 (ko) 2020-04-22
HK1212321A1 (en) 2016-06-10
ES2658413T3 (es) 2018-03-09
JP2015536316A (ja) 2015-12-21
TW201418202A (zh) 2014-05-16
ZA201503574B (en) 2016-01-27
HRP20180189T1 (hr) 2018-04-20
PL2909169T3 (pl) 2018-07-31
US9487477B2 (en) 2016-11-08
IL237733B (en) 2019-03-31
EP2722327A1 (en) 2014-04-23
JP6317358B2 (ja) 2018-04-25
KR20150072454A (ko) 2015-06-29
BR112015008931B1 (pt) 2021-05-18
AU2013336738A1 (en) 2015-04-09
IN2015DN02807A (es) 2015-09-11
CA2884914A1 (en) 2014-05-01
CY1119913T1 (el) 2018-06-27
DK2909169T3 (en) 2018-02-26
RS56896B1 (sr) 2018-04-30
BR112015008931A2 (pt) 2017-07-04
US9278921B2 (en) 2016-03-08
AU2013336738B2 (en) 2017-05-18
EP2909169A1 (en) 2015-08-26
EP2909169B1 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
CY1120805T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012076466A3 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MY172574A (en) Dicaffeoylquinic acid-containing drink
WO2012051407A3 (en) Molecular containers and methods of making and using same
IN2011KN05169A (es)
MX2015005059A (es) Fase cristalina de (3s,3s&#39;) 4,4&#39;-disulfanodiilbis(acido 3-aminobutano-1-sulfonico) con l-lisina.
CA2901220C (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
WO2015071299A3 (en) Stable pharmaceutical glycylcycline compositions
MY181682A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
WO2011152657A3 (en) Acetyl-l-carnitine malate, process for preparing the same, and pharmaceutical composition comprising the same
TN2014000106A1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2011092655A3 (en) Mentha suaveolens essential oil and therapeutic activities thereof
WO2013064326A3 (de) Arjunolsäure zur erhöhung der sebumproduktion
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MX2012013055A (es) Un procedimiento mejorado para purificar el complejo de cloruro de benzalconio-dialil oxido de disulfuro modificado y usos.
UA99014C2 (ru) Метиловый эстер n-[(2-оксоиндолинилиден-3)-2-оксиацетил]аминоуксусной кислоты, который проявляет противовоспалительное действие
UA100962C2 (ru) Фармацевтипческой сустанции соли аминокислоты l-лизина и эсцина

Legal Events

Date Code Title Description
FG Grant or registration